Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 19/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 17/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 17/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1058590 | 1.00 | SLC6A4 (0.50) | SLC6A4SLC6A2SLC6A3CYP2D6HTR2C | |
| SCHEMBL1059880 | 1.00 | SLC6A4 (0.50) | SLC6A4SLC6A2SLC6A3CYP2D6HTR2C | |
| SCHEMBL1058588 | 1.00 | SLC6A4 (0.50) | SLC6A4SLC6A2SLC6A3CYP2D6HTR2C | |
| SCHEMBL1059879 | 1.00 | SLC6A4 (0.50) | SLC6A4SLC6A2SLC6A3CYP2D6HTR2C | |
| SCHEMBL935943 | 0.95 | SLC6A4 (0.48) | SLC6A4SLC6A2SLC6A3CYP2D6HTR2C | |
| SCHEMBL1061624 | 0.86 | SLC6A4 (0.65) | SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL1060652 | 0.86 | SLC6A4 (0.65) | SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL1059132 | 0.86 | SLC6A2 (0.50) | SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL1059133 | 0.86 | SLC6A2 (0.50) | SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL1061335 | 0.86 | SLC6A4 (0.65) | SLC6A4SLC6A2SLC6A3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257243-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257243-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | HTR6, SLC6A4, SLC6A2 | SLC6A4 2/4885SLC6A2 3/4885SLC6A3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.